Abstract 399P
Background
Currently in Indonesia, colorectal cancer (CRC) is the third most commonly occurring cancer in men and the fourth in women. CRC is mostly diagnosed in the advanced stage, it’s probably caused by the difficulties in detecting colorectal cancer. Identifying risk factors of CRC is very crucial to prevent CRC. CRC risk is expected to rise continually due to dietary patterns, smoking, lack of physical activities, and other practices. This study describes the prevalence of risk factors for CRC in healthy residents of Suluhan village, Bangli District, Bali Province.
Methods
A pre-experimental cross-sectional study-based community was conduct on 18th – 19th May 2019 in Suluhan village to collect data from 77 healthy residents using validated questionnaire. We measured sociodemographic characteristics, physical activity, dietary habits, and lifestyle as risk factors of CRC. Analysis of data using chi-square with p-value ≤0.05 is categorized as significant.
Results
77 respondents were involved in this study with a mean age of 41.94 ± 9.448 years. The majority of participants were female (61 %). Mostly the residents didn’t know CRC (80.6%). The commonest risk factors for CRC among the participants were overconsumption of red meat (2 times/week and >3 times/week) (67.6 %), overweight and obesity (62.4 %), limited consumption of vegetables (62.3 %), low of physical activities (44.1%), smoking (28.6%), and limited consumption of diet fiber (10.4%). Lack of physical activity was found significantly higher in females (p = 0,000), otherwise smoking (p = 0,000) is higher in males.
Conclusions
We conclude that the highest risk factor of CRC in Suluhan village is the overconsumption of red meat, followed by overweight and obesity, limited consumption of vegetables, low physical activities, smoking, and limited consumption of diet fiber sequentially. Dietary and lifestyle risk factors for CRC are prevalent in Suluhan village and likely to increase CRC incidence if educational interventions are not implemented. Greater attention in improving residents’ knowledge of CRC risk is needed to prevent CRC in Suluhan village.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
195P - HGCSG1601: A retrospective cohort study of the efficacy and safety of nab-paclitaxel plus gemcitabine (nab-P+GEM) for unresectable locally advanced pancreatic cancer (LAPC)
Presenter: Aya Tanimoto
Session: Poster display session
Resources:
Abstract
196P - The tolerability and efficacy of FOLFIRINOX in gastro-oesophageal carcinoma
Presenter: Nicholas Travers
Session: Poster display session
Resources:
Abstract
197TiP - GLOW: Zolbetuximab + CAPOX compared with placebo + CAPOX as first-line treatment for patients with Claudin18.2+/HER2– Locally advanced unresectable or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma: A randomized phase III study
Presenter: Rui-Hua Xu
Session: Poster display session
Resources:
Abstract
198TiP - SPOTLIGHT: Comparison of zolbetuximab or placebo + mFOLFOX6 as first-line treatment in patients with claudin18.2+/HER2– locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (GEJ): A randomized phase III study
Presenter: Kensei Yamaguchi
Session: Poster display session
Resources:
Abstract
199TiP - Phase III (COSMIC-312) study of cabozantinib (C) in combination with atezolizumab (A) vs sorafenib (S) in patients (pts) with advanced hepatocellular carcinoma (aHCC) who have not received previous systemic anticancer therapy
Presenter: Thomas Yau
Session: Poster display session
Resources:
Abstract
200P - Apalutamide (APA) plus androgen deprivation therapy (ADT) for metastatic castration-sensitive prostate cancer (mCSPC): Analysis of pain and fatigue in the TITAN study
Presenter: Byung Ha Chung
Session: Poster display session
Resources:
Abstract
201P - Efficacy and safety of darolutamide in non-metastatic castration-resistant prostate cancer (nmCRPC) in the ARAMIS trial
Presenter: Jacob See-tong Pang
Session: Poster display session
Resources:
Abstract
202P - What is the best first-line therapy for metastatic castration-sensitive prostate cancer in 2019? A network meta-analysis
Presenter: Tsz Him So
Session: Poster display session
Resources:
Abstract
203P - Long term outcomes of 2-weekly docetaxel in metastatic high-volume hormone sensitive prostate cancer
Presenter: Suhas Singla
Session: Poster display session
Resources:
Abstract
204P - The effect of radium-223 therapy in agent orange related veterans with metastatic castrate resistance prostate carcinoma (CRPC)
Presenter: Andrew Liman
Session: Poster display session
Resources:
Abstract